NASDAQ · ABVX
Abivax SA financials
$98.50+1.70%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $5.4M | $13.0M | $5.1M |
| Gross profit | $5.4M | $13.0M | $5.1M |
| Gross margin | 100.0% | 100.0% | 100.0% |
| Operating income | -$288.7M | -$180.0M | -$140.8M |
| Net income | -$394.3M | -$183.4M | -$163.3M |
| Net margin | −7354.5% | −1415.7% | −3197.1% |
| Diluted EPS | $-5.67 | $-2.91 | $-3.79 |
| EBITDA | -$287.4M | -$178.9M | -$140.0M |
| Operating cash flow | -$189.0M | -$160.3M | -$107.4M |
| Free cash flow | -$189.2M | -$161.0M | -$107.7M |
| Diluted shares | 69.5M | 63.0M | 43.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $606.2M | $150.1M | $278.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $2.2M | $100.1M | $61.3M |
| Total assets | $685.6M | $213.6M | $361.6M |
| Total liabilities | $151.5M | $171.3M | $144.9M |
| Shareholders' equity | $534.1M | $42.2M | $216.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology